145 related articles for article (PubMed ID: 16507510)
1. Inhibitory effects of polyphenolic compounds on human arylamine N-acetyltransferase 1 and 2.
Kukongviriyapan V; Phromsopha N; Tassaneeyakul W; Kukongviriyapan U; Sripa B; Hahnvajanawong V; Bhudhisawasdi V
Xenobiotica; 2006 Jan; 36(1):15-28. PubMed ID: 16507510
[TBL] [Abstract][Full Text] [Related]
2. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.
Grant DM; Blum M; Beer M; Meyer UA
Mol Pharmacol; 1991 Feb; 39(2):184-91. PubMed ID: 1996083
[TBL] [Abstract][Full Text] [Related]
3. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
4. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2.
Smelt VA; Mardon HJ; Sim E
Pharmacol Toxicol; 1998 Oct; 83(4):149-57. PubMed ID: 9820875
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of potent, selective, and efficacious inhibitors of human arylamine N-acetyltransferase 1.
Leggett CS; Doll MA; Salazar-González RA; Habil MR; Trent JO; Hein DW
Arch Toxicol; 2022 Feb; 96(2):511-524. PubMed ID: 34783865
[TBL] [Abstract][Full Text] [Related]
6. N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast.
Williams JA; Stone EM; Fakis G; Johnson N; Cordell JA; Meinl W; Glatt H; Sim E; Phillips DH
Pharmacogenetics; 2001 Jul; 11(5):373-88. PubMed ID: 11470991
[TBL] [Abstract][Full Text] [Related]
7. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.
Hein DW; Doll MA; Rustan TD; Gray K; Feng Y; Ferguson RJ; Grant DM
Carcinogenesis; 1993 Aug; 14(8):1633-8. PubMed ID: 8353847
[TBL] [Abstract][Full Text] [Related]
8. Liver-selective expression of human arylamine N-acetyltransferase NAT2 in transgenic mice.
Sugamori KS; Brenneman D; Grant DM
Drug Metab Dispos; 2011 May; 39(5):882-90. PubMed ID: 21317369
[TBL] [Abstract][Full Text] [Related]
9. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli.
Dupret JM; Goodfellow GH; Janezic SA; Grant DM
J Biol Chem; 1994 Oct; 269(43):26830-5. PubMed ID: 7929420
[TBL] [Abstract][Full Text] [Related]
10. Molecular and Functional Characterization of N-Acetyltransferases NAT1 and NAT2 in Cynomolgus Macaque.
Uno Y; Murayama N; Yamazaki H
Chem Res Toxicol; 2018 Nov; 31(11):1269-1276. PubMed ID: 30358977
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine.
Ware JA; Svensson CK
Biochem Pharmacol; 1996 Nov; 52(10):1613-20. PubMed ID: 8937477
[TBL] [Abstract][Full Text] [Related]
12. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
[TBL] [Abstract][Full Text] [Related]
13. Human arylamine N-acetyltransferase 1: in vitro and intracellular inactivation by nitrosoarene metabolites of toxic and carcinogenic arylamines.
Liu L; Wagner CR; Hanna PE
Chem Res Toxicol; 2008 Oct; 21(10):2005-16. PubMed ID: 18759501
[TBL] [Abstract][Full Text] [Related]
14. Cyanamide-mediated Inhibition of N-acetyltransferase 1.
Dierolf D; Scheitza S; Bonifas J; Blömeke B
Toxicology; 2012 Dec; 302(1):1-10. PubMed ID: 22835378
[TBL] [Abstract][Full Text] [Related]
15. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines.
Liu L; Wagner CR; Hanna PE
Chem Res Toxicol; 2009 Dec; 22(12):1962-74. PubMed ID: 19842618
[TBL] [Abstract][Full Text] [Related]
16. Expression of arylamine N-acetyltransferase in human intestine.
Hickman D; Pope J; Patil SD; Fakis G; Smelt V; Stanley LA; Payton M; Unadkat JD; Sim E
Gut; 1998 Mar; 42(3):402-9. PubMed ID: 9577349
[TBL] [Abstract][Full Text] [Related]
17. The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress.
Dairou J; Malecaze F; Dupret JM; Rodrigues-Lima F
Mol Pharmacol; 2005 Apr; 67(4):1299-306. PubMed ID: 15644493
[TBL] [Abstract][Full Text] [Related]
18. Human N-acetylation of benzidine: role of NAT1 and NAT2.
Zenser TV; Lakshmi VM; Rustan TD; Doll MA; Deitz AC; Davis BB; Hein DW
Cancer Res; 1996 Sep; 56(17):3941-7. PubMed ID: 8752161
[TBL] [Abstract][Full Text] [Related]
19. Control of the mutagenicity of arylamines by protein kinases and phosphatases: II. Lack of response of rat liver N-acetyl transferases to phosphorylation modulators.
Padma PR; Oesch-Bartlomowicz B; Hengstler JG; Oesch F
Arch Toxicol; 1997; 71(10):655-9. PubMed ID: 9332704
[TBL] [Abstract][Full Text] [Related]
20. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.
Sugamori KS; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
Mol Pharmacol; 2003 Jul; 64(1):170-9. PubMed ID: 12815173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
